A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer

被引：6
作者：
Kwon, Daniel Hyuck-Min [1 ,2 ]
Friedlander, Terence [1 ,2 ]
机构：
[1] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷
关键词：
ABIRATERONE; THERAPY;
D O I：
10.21037/atm.2019.09.21
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer
    Bilgin, Burak
    Sendur, Mehmet A. N.
    Hizal, Mutlu
    Akinci, Muhammed Bulent
    Dede, Didem Sener
    Yalcin, Bulent
    [J]. FUTURE ONCOLOGY, 2017, 13 (22) : 1911 - 1913
  • [22] Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons
    Hamid, Anis A.
    Morris, Michael J.
    Davis, Ian D.
    [J]. EUROPEAN UROLOGY FOCUS, 2019, 5 (02): : 165 - 167
  • [23] Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?
    Adashek, Jacob J.
    Reed, Jarred P.
    Tandon, Ankita
    Freedland, Stephen J.
    Posadas, Edwin
    Bhowmick, Neil
    Chung, Leland W.
    Freeman, Michael
    Figlin, Robert A.
    Gong, Jun
    [J]. CLINICAL GENITOURINARY CANCER, 2020, 18 (06) : 425 - 428
  • [24] Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
    Yekeduz, Emre
    McKay, Rana R.
    Gillessen, Silke
    Choueiri, Toni K.
    Urun, Yuksel
    [J]. ONCOLOGIST, 2023, 28 (07) : 596 - 603
  • [25] Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration
    Freedland, Stephen J.
    Sandin, Rickard
    Sah, Janvi
    Emir, Birol
    Mu, Qiao
    Ratiu, Anna
    Hong, Agnes
    Serfass, Lucile
    Tagawa, Scott T.
    [J]. CANCER MEDICINE, 2021, 10 (23): : 8570 - 8580
  • [26] Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting
    Sayegh, Nicolas
    Tripathi, Nishita
    Nussenzveig, Roberto H.
    Thomas, Vinay Mathew
    Tandar, Clara
    Goel, Divyam
    Nordblad, Blake
    Sahu, Kamal Kant
    Li, Haoran
    Maughan, Benjamin L.
    Agarwal, Neeraj
    Swami, Umang
    [J]. EUROPEAN UROLOGY FOCUS, 2023, 9 (01): : 106 - 109
  • [27] PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer
    Sutera, Philip
    Kim, Jongmyung
    Kumar, Ritesh
    Deek, Rebecca A.
    Stephenson, Ryan
    Mayer, Tina
    Saraiya, Biren
    Ghodoussipour, Saum
    Jang, Thomas
    Golombos, David
    Packiam, Vignesh
    Ennis, Ronald
    Hathout, Lara
    Jabbour, Salma K.
    Guler, Ozan
    Onal, Cem
    Tran, Phuoc T.
    Deek, Matthew P.
    [J]. PROSTATE, 2024, 84 (14) : 1301 - 1308
  • [28] APPROACH TO THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CARCINOMA: A SINGLE CENTER EXPERIENCE
    Semiz, Huseyin Salih
    Keskinkilic, Merve
    Ellez, Halil Ibrahim
    Arayici, Mehmet Emin
    Karaoglu, Aziz
    [J]. JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, 2022, 6 (01): : 296 - 304
  • [29] HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer
    Hearn, Jason W. D.
    Sweeney, Christopher J.
    Almassi, Nima
    Reichard, Chad A.
    Reddy, Chandana A.
    Li, Hong
    Hobbs, Brian
    Jarrard, David F.
    Chen, Yu-Hui
    Dreicer, Robert
    Garcia, Jorge A.
    Carducci, Michael A.
    DiPaola, Robert S.
    Sharifi, Nima
    [J]. JAMA ONCOLOGY, 2020, 6 (04)
  • [30] De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?
    Iacovelli, Roberto
    Ciccarese, Chiara
    Mosillo, Claudia
    Tortora, Giampaolo
    [J]. CLINICAL GENITOURINARY CANCER, 2018, 16 (06) : 482 - 484
12345